Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654433 · ClinicalTrials.gov registry record · Phase 3
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
A Phase 3 study, sponsored by Aldagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00654433 is a Phase 3 study that was terminated before completion, run by Aldagen. The registered enrollment target is 40 participants.
The verdict
NCT00654433, a Phase 3 study, was terminated before completion, sponsored by Aldagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion. The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.
Interventions
- BIOLOGICAL ALD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654433
The ClinicalTrials.gov registry entry for NCT00654433 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldagen, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALD-101 is the first listed.
NCT00654433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654433 about?
NCT00654433 is a clinical study titled "ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases". Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion...
What is the current status of trial NCT00654433?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2008-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00654433?
The interventions under investigation include: ALD-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00654433?
This trial is sponsored by Aldagen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.